Deal Tracker · Countries
South Korea pharma licensing deals
6 licensing deals involving South Korea tracked by EPT (2025–2026). Most active: Arcera Life Sciences, AriBio, Autotelic Bio & Bukwang Pharmaceutical. Latest: Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).
- EPT has tracked 6 South Korea pharma licensing deals (2025–2026), 4 of them announced in 2026.
- The countries that appear most often are Saudi Arabia (2), UAE (2), Bahrain (1) & Egypt (1).
- Values were disclosed for 3 of 6 deals, totalling $696.7m; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
- The most active companies: Arcera Life Sciences (2).
- Bukwang Pharmaceutical → NASAQLicensing · GCC · $2.7m · 4 Nov 2026
- Autotelic Bio → MenariniLicensing · MENA · Undisclosed · 26 Oct 2026
- Dongkook Pharmaceutical → Faes FarmaLicensing · Latin America · See terms · 1 Jul 2026
- Daewoong Pharmaceutical → Arcera Life SciencesLicensing · MENA · $94m · 29 Jun 2026
- Celltrion → Hikma PharmaceuticalsLicensing · MENA · 6 Oct 2025
- AriBio → Arcera Life SciencesLicensing · Global (LMICs) · $600m · 10 Jun 2025
Most active companies
Largest disclosed deals
- AriBio → Arcera Life Sciences · $600m · Licensing · 10 Jun 2025
- Daewoong Pharmaceutical → Arcera Life Sciences · $94m · Licensing · 29 Jun 2026
- Bukwang Pharmaceutical → NASAQ · $2.7m · Licensing · 4 Nov 2026
Questions
- How many South Korea pharma licensing deals has EPT tracked?
- 6 as of 4 Nov 2026, covering 2025–2026; 4 were announced in 2026. The most recent is Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).
- Which companies are most active in South Korea pharma licensing deals?
- Arcera Life Sciences (2 deals).
- What is the largest disclosed South Korea pharma licensing deal?
- AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Bukwang Pharmaceutical → NASAQ: $2.7m (Licensing, 4 Nov 2026). Values are as announced by the parties.
Browse deals
By region
GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)
By country
Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)
By deal type
Licensing (56) · Distribution (41) · Technology transfer / Localization (39) · Partnership / Collaboration (35) · M&A / Acquisition (21) · Equity / Investment (18) · Joint venture (11) · Supply / Manufacturing (10)
Popular searches
MENA pharma licensing deals (25) · Saudi Arabia pharma licensing deals (24) · GCC pharma distribution deals (21) · GCC pharma partnerships (19) · China pharma licensing deals (17) · UAE pharma distribution deals (17) · GCC pharma localization & tech-transfer deals (15) · Saudi Arabia pharma distribution deals (14) · UAE pharma partnerships (13) · UAE pharma licensing deals (12) · Global (LMICs) pharma licensing deals (11) · India pharma licensing deals (11) · GCC pharma licensing deals (10) · MENA pharma partnerships (10) · Saudi Arabia pharma localization & tech-transfer deals (10) · MENA pharma localization & tech-transfer deals (9) · United States pharma licensing deals (9) · Egypt pharma localization & tech-transfer deals (8) · Saudi Arabia pharma partnerships (8) · CIS & Central Asia pharma localization & tech-transfer deals (7) · Kazakhstan pharma localization & tech-transfer deals (7) · MENA pharma distribution deals (7) · MENA pharma M&A deals (7) · United States pharma distribution deals (7)
By company
ADCAN Pharma (13) · Mubadala Bio (8) · Jamjoom Pharma (7) · SPIMACO (7) · Arcera Life Sciences (6) · Hikma Pharmaceuticals (6) · Bio-Thera Solutions (6) · Avalon Pharma (5) · Tabuk Pharmaceuticals (5) · Local Content and Government Procurement Authority (5) · Kazakhstan Ministry of Health (5) · Eva Pharma (4) · Sandoz (4) · Department of Health – Abu Dhabi (4) · Biocon (4) · Groupe Saidal (4) · Gilead Sciences (3) · Dr. Reddy's Laboratories (3) · Emirates Drug Establishment (3) · Novo Nordisk (3) · Khazaen Economic City (3) · Galenicum (3) · Roche (3) · Laprophan (3) · Sanofi (3) · Gen İlaç (3) · Taiba Healthcare (3) · Dar Al Dawa (3) · Lifera (3) · Celltrion (2) · Viatris (2) · Rem3dy Health (2) · AMA Medical Manufacturing (2) · Afreximbank (2) · M42 (2) · Abbott (2) · DKSH (2) · Adalvo (2) · Rameda (2) · Menarini (2) · Korea United Pharm (2) · Samsung Bioepis (2) · AstraZeneca (2) · MS Pharma (2) · LifePharma (2) · Duopharma Biotech (2) · JCR Pharmaceuticals (2) · Philex Pharmaceuticals (2) · Lotus Pharmaceutical (2) · Elpen (2) · Dhofar Pharmaceutical Industries (2) · Accord Healthcare (2) · CCL Pharmaceuticals (2) · Abdi İbrahim (2) · Nordic Pharma (2) · UNIMED Laboratories (2) · Minapharm (2) · SaudiVax (2) · Faes Farma (2) · AJA Pharma (2) · VACSERA (2) · Bayer (2) · Shanghai Henlius Biotech (2) · Julphar (2)
By therapeutic area
Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)